Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis
- PMID: 31054211
- DOI: 10.1111/bju.14798
Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis
Abstract
Objective: To evaluate the prognostic significance of lymph node count (LNC) at post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND) in metastatic non-seminomatous germ cell tumour (NSGCT) using the Surveillance, Epidemiology, and End Results (SEER) database and National Cancer Database (NCDB).
Patients and methods: SEER (2000-2013, n = 572) and NCDB (2004-2013, n = 731) identified patients undergoing PC-RPLND for Stage II and III NSGCT. Correlation between linear or categorial variables and LNC was conducted using Spearman's rank correlation or Kruskal-Wallis test by ranks. Patients were stratified by ≤20, 21-40, and >40 LNs for Kaplan-Meier analysis. Cox proportional hazards models evaluated the association of LNC at PC-RPLND with overall mortality (OM) in the NCDB and cancer-specific mortality (CSM) in the SEER database. The relationship between LNC and OM or CSM was also modelled as a non-linear function to determine a threshold for survival benefit.
Results: Amongst all patients, the median (interquartile range) LNC was 17 (3-26) LNs in the NCDB, and 18 (6-31) LNs in the SEER database. More recent diagnosis year, higher hospital volume, higher median income, private insurance status, and positive LNC were associated with greater total LNC in one or both databases (P < 0.05). On Kaplan-Meier analysis, >40 LNs was associated with 5-year cancer-specific survival (CSS) of 99% and overall survival (OS) of 96%, whereas ≤20 LNs had a 5-year CSS of 91% and OS of 78% (CSS, P = 0.04; OS, P < 0.01). Risk-adjusted Cox model showed increasing LNC (per node) was inversely associated with OM (hazard ratio [HR] 0.96, 95% confidence interval [CI], 0.94-0.98; P < 0.01) and CSM (HR 0.96, 95% CI, 0.94-0.99; P = 0.01). Non-linear modelling showed the greatest benefit in OM at between 10 and 20 LNs, but continued survival benefit for OM and CSM beyond 20 LNs.
Conclusions: Greater LNC during PC-RPLND appears to be associated with improved CSS and OS in NSGCT. Our data support the role of thorough RPLND for post-chemotherapy metastatic NSGCT.
Keywords: #TesticularCancer; #tscsm; chemotherapy; lymph node count; metastatic non-seminoma; retroperitoneal lymphadenectomy.
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.
Similar articles
-
Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer.J Urol. 2022 May;207(5):1057-1066. doi: 10.1097/JU.0000000000002369. Epub 2022 Jan 3. J Urol. 2022. PMID: 34978466
-
Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.Eur Urol Oncol. 2018 Aug;1(3):242-251. doi: 10.1016/j.euo.2018.04.005. Epub 2018 Jun 6. Eur Urol Oncol. 2018. PMID: 31058267 Free PMC article.
-
Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.Cancer. 2015 Dec 15;121(24):4369-75. doi: 10.1002/cncr.29678. Epub 2015 Sep 15. Cancer. 2015. PMID: 26371446
-
Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.Oncol Res Treat. 2018;41(6):370-378. doi: 10.1159/000489508. Epub 2018 May 17. Oncol Res Treat. 2018. PMID: 29772568 Review.
-
Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.Urol Oncol. 2019 Mar;37(3):209-218. doi: 10.1016/j.urolonc.2018.09.009. Epub 2018 Nov 13. Urol Oncol. 2019. PMID: 30446455 Free PMC article. Review.
Cited by
-
How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology.Mil Med Res. 2023 Oct 31;10(1):50. doi: 10.1186/s40779-023-00488-2. Mil Med Res. 2023. PMID: 37899480 Free PMC article. Review.
-
The prognostic value of lymph node ratio in comparison to positive lymph node count in penile squamous cell carcinoma.Int Urol Nephrol. 2021 Dec;53(12):2527-2540. doi: 10.1007/s11255-021-02996-3. Epub 2021 Sep 28. Int Urol Nephrol. 2021. PMID: 34585313 Free PMC article.
-
Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors.World J Urol. 2021 Jun;39(6):1977-1984. doi: 10.1007/s00345-020-03403-9. Epub 2020 Aug 14. World J Urol. 2021. PMID: 32797261
-
Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer.Asian J Urol. 2024 Jan;11(1):121-127. doi: 10.1016/j.ajur.2022.03.010. Epub 2022 Jul 30. Asian J Urol. 2024. PMID: 38312811 Free PMC article.
-
Additional surgical procedures and perioperative morbidity in post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer in two intermediate volume hospitals.World J Urol. 2021 Mar;39(3):839-846. doi: 10.1007/s00345-020-03229-5. Epub 2020 May 5. World J Urol. 2021. PMID: 32372160 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7-30
-
- Albers P, Albrecht W, Algaba F et al. Guidelines on testicular cancer: 2015 update. Eur Urol 2015; 68: 1054-68
-
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology[Internet]. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 2017
-
- Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 2007; 110: 1235-40
-
- Steiner H, Peschel R, Bartsch G. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary? BJU Int 2008; 102: 310-4
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical